Anavex Life Sciences Corp (AVXL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.42 (+0.41%), Market cap $0.31B, 52-week low–high $2.74 ~ $13.41.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally availab
Financial statements, price targets, institutional (13F) holdings and related news for Anavex Life Sciences Corp are updated in real time on BlackAll Trade.
Anavex Life Sciences Corp trades at $2.42 (+0.41%). Real-time quotes and charts are available on BlackAll Trade.
Anavex Life Sciences Corp has a market cap of about $0.31B.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neur